Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 19/20 | 0.77 |
| ▸ | CDK9 | P50750 | 12/20 | 0.77 |
| ▸ | CCNH | P51946 | 12/20 | 0.77 |
| ▸ | CCNK | O75909 | 11/20 | 0.77 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.77 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.77 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.77 |
| ▸ | CDK13 | Q14004 | 9/20 | 0.60 |
| ▸ | CDK2 | P24941 | 7/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.60 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22778393 | 1.00 | CDK7 (0.77) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL18069866 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL16665073 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL18047336 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL18047286 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL16665075 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL16665076 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL20764205 | 0.87 | CDK7 (0.61) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL16665077 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 | |
| SCHEMBL16665074 | 0.87 | CDK7 (1.00) | CDK7CDK9CCNHCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-11-07 | — | — | US | disclosed |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| WO-2016058544-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337940-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CDK9 3/4885CCNH 32/4885 |
| US-10308648-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CDK9 3/4885CCNH 32/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CDK9 3/4885CCNH 32/4885 |
| US-20210061803-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CDK9 3/4885CCNH 32/4885 |
| US-10865206-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CDK9 3/4885CCNH 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.